Portal de Periódicos da CAPES

The Second Generation Sulfonylureas: Glipizide and Glyburide

1985; SAGE Publishing; Volume: 11; Issue: 3 Linguagem: Inglês

10.1177/014572178501100305

1554-6063

Danial E. Baker, R. Keith Campbell,

Pancreatic function and diabetes

Glyburide and glipizide are approved by the FDA for treatment of symptomatic and asymp tomatic NIDDM patients in whom hyperglycemia cannot be satisfactorily controlled by diet and exercise. Pharmacology studies suggest that glyburide and glipizide sensitize the beta cells of the pancreas to release insulin only in the presence of elevated serum glucose levels. Long-term efficacy appears to depend on extrapancreatic effects, suppressing hepatic glucose production, and improved postreceptor insulin activity.